Neuronal response of peroxisomal and peroxisome-related proteins to chronic and acute Aβ injury

Current Alzheimer Research

Volumn 6, Issue 3, 2009, Pages 238-251

  Cimini, A ^a   Benedetti, E ^a   D'Angelo, B ^a   Cristiano, L ^a   Falone, S ^a   Di Loreto, S ^b   Amicarelli, F ^a   Ceru M P ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Ospedale S Maria di Collemaggio   (Italy)

Author keywords

Anti oxidant enzymes; Lipid metabolism; Neurodegeneration; PPAR

Indexed keywords

ACETYL COENZYME A ACETYLTRANSFERASE; ACYL COENZYME A OXIDASE; AMYLOID BETA PROTEIN[25-35]; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE TRANSFERASE P1; INSULINASE; MANGANESE SUPEROXIDE DISMUTASE; MEMBRANE PROTEIN; PEROXISOMAL MEMBRANE PROTEIN 70; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; LIPID METABOLISM; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PEROXISOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION;

AMYLOID BETA-PROTEIN; ANIMALS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; EMBRYO, MAMMALIAN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTATHIONE S-TRANSFERASE PI; INDOLES; INSULYSIN; NERVE TISSUE PROTEINS; NEURONS; PEPTIDE FRAGMENTS; PEROXIDASES; PPAR ALPHA; RATS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS;

EID: 67149112260     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509788486518     Document Type: Article

References (60)

1. Glenner GG and Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 120: 885-890 (1984).
2. Masters CL, Multhaup G, Simms G, Pottigiesser J, Martins RN and Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 4: 2757-2763 (1985).
3. Younkin SG. The role of A beta 42 in Alzheimer's disease. J Physiol Paris 92: 289-292 (1998).
4. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766 (2001). (Pubitemid 32267077)
5. Origlia N, Righi M, Capsoni S, Cattaneo A, Fang F, Stern DM, et al. Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 28: 3521-3530 (2008).
6. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156: 15-20 (2000).
7. Blasko I, Veerhuis R, Stampfer-Kountchev M, Saurwein-Teissl M, Eikelenboom P and Grubeck-Loebenstein B. Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol Dis 7: 682-689 (2000). (Pubitemid 32044292)
8. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation Nat Neurosci 4: 887-893 (2001).
9. Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's sindrome. Neuron 33: 677-688 (2002).
10. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421 (2003).
11. Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, et al. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down sindrome. Neurobiol Aging 25: 1263-1272 (2004).
12. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C and Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45: 1092-1096 (1995).
13. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252: 711-715 (1998).
14. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137: 149-155 (2002).
15. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, Van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349: 151-154 (1997).
16. Luchsinger JA, Tang MX, Stern Y, Shea S and Mayeux R. 2001. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 154: 635-641 (2001). (Pubitemid 32888781)
17. McIlroy SP, Dynan KB, Lawson JT, Patterson CC and Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in "Northern Ireland Stroke". 33: 2351-2356 (2002).
18. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, et al. Stroke and the risk of Alzheimer disease. Arch Neurol 60: 1707-1712 (2003).
19. Van der Zand A, Braakman I, Geuze HJ, Tabak HF. The return of the peroxisome. J Cell Sci 119: 989-994 (2006).
20. Citkowitz E and Holtzman E. Peroxisomes in dorsal root ganglia. J Histochem Cytochem 21: 34-41 (1973).
21. McKenna O, Arnold G and Holtzman E. Microperoxisome distribution in the central nervous system of the rat. Brain Res 117: 181-194 (1976).
22. Ishikawa T, Kawai C, Sano M and Minatogawa Y. Peroxisomes exist in growth cones and move anterogradely and retrogradely in neurites of PC12D cells. Exp Cell Res 266: 260-269 (2001). (Pubitemid 32579231)
23. Stamer K, Vogel R, Thies E, Mandelkow E and Mandelkowm EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Biol Chem 156: 1051-1063 (2002). (Pubitemid 34839854)
24. Santos MJ, Quintanilla RA, Toro A, Grandy R, Dinamarca MC, Godoy JA, et al. Peroxisomal proliferation protects from β-Amyloid neurodegeneration. J Biol Chem 80: 41057-41068 (2005).
25. Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1 - 42) and A beta(25 - 35). J Am Chem Soc 123: 5625-5631 (2001). (Pubitemid 32904694)
26. White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 18: 459-465 (2005). (Pubitemid 40332705)
27. Munõz FJ and Inestrosa NC. Neurotoxicity of acetylcholinesterase amyloid beta-peptide aggregates is dependent on the type of Abeta peptide and the AChE concentration present in the complexes. FEBS Lett 450: 205-209 (1999). (Pubitemid 29219515)
28. Naiki H, Higuchi K, Nakakuki K and Takeda T. Kinetic analysis of amyloid fibril polymerization in vitro. Lab Invest 65: 104-110 (1991).
29. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 16: 881-891 (1996).
30. Alvarez A, Alarcón R, Opazo C, Campos EC, Muñoz FJ, Calderón FH, et al. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 18: 3213-3223 (1998).
31. Schrader M and Fahimi HD. Mammalian peroxisomes and reactive oxygen species. Histochem Cell Biol 122: 383-393 Review (2004). (Pubitemid 39506595)
32. Farioli-Vecchioli S, Moreno S and Cerù MP. Immunocytochemical localization of acyl-CoA oxidase in the rat central nervous system. J Neurocytol 30: 21-33 (2001). (Pubitemid 33078956)
33. Terlecky SR, Koepke JI and Walton PA. Peroxisomes and aging. Biochim Biophys Acta 1763: 1749-1754 Review (2006).
34. Jellinger KA. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14: 115-140 (1999). (Pubitemid 29086113)
35. Marlatt M, Lee HG, Perry G, Smith MA, Zhu X. Sources and mechanisms of cytoplasmic oxidative damage in Alzheimer's disease. Acta Neurobiol Exp (Wars.) 64: 81-87 (2004). (Pubitemid 38453808)
36. Röhrdanz E, Schmuck G, Ohler S, Kahl R. The influence of oxidative stress on catalase and MnSOD gene transcription in astrocytes. Brain Res 900: 28-36 (2001). (Pubitemid 32452272)
37. Powers JM. Normal and defective neuronal membranes: structure and function: neuronal lesions in peroxisomal disorders. J Mol Neurosci 16: 285-287 (2001).
38. Su HM, Moser AB, Moser HW and Watkins PA. Peroxisomal straight-chain Acyl-CoA oxidase and D-bifunctional protein are essential for the retroconversion step in docosahexaenoic acid synthesis. J Biol Chem 276: 38115-38120 (2001). (Pubitemid 37384065)
39. Ferdinandusse S, Denis S, Mooijer PA, Zhang Z, Reddy JK, Spector AA, et al. Identification of the peroxisomal beta-oxidation enzymes involved in the biosynthesis of docosahexaenoic acid. J Lipid Res 42: 1987-1995 (2001).
40. Selkoe DJ. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest 110: 1375-1381. Review (2002). (Pubitemid 35396905)
41. Horrocks LA and Farooqui AA. Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot Essent Fatty Acids 70: 361-372. Review (2004). (Pubitemid 38429269)
42. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J Lipid Res 48: 2485-2498 (2007).
43. Razeto A, Mattiroli F, Carpanelli E, Aliverti A, Pandini V, Coda A, et al. The crucial step in ether phospholipid biosynthesis: structural basis of a noncanonical reaction associated with a peroxisomal disorder. Structure 15: 683-692 (2007).
44. Latruffe N, Cherkaoui Malki M, Nicolas-Frances V, Jannin B, Clemencet MC, Hansmannel F, et al. Peroxisome-proliferator-activated receptors as physiological sensors of fatty acid metabolism: molecular regulation in peroxisomes. Biochem Soc Trans 29: 305-309 (2001).
45. Poynter ME and Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273: 32833-32841 (1998). (Pubitemid 28557672)
46. Berger J and Moller DE. The mechanisms of action of PPARs. Annu Rev Med 53: 409-435 Review (2002).
47. Howroyd P, Swanson C, Dunn C, Cattley RC and Corton JC. Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha). Toxicol Pathol 32: 591-599 (2004). (Pubitemid 39258464)
48. Hashimoto T, Fujita T, Usada N, Cook W, Qi C, Peters JM, et al. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype J Biol Chem 274: 19228-19236 (1999).
49. Kim M, Hersh LB, Leissring MA, Ingelsson M, Matsui T, Farris W, et al. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem 282: 7825-7832 (2007).
50. Authier F, Posner BI and Bergeron JJ. Insulin-degrading enzyme. Clin Invest Med 19: 149-160 Review (1996). (Pubitemid 26225900)
51. Morita M, Kurochkin IV, Motojima K, Goto S, Takano T, Okamura S, et al. Insulin-degrading enzyme exists inside of rat liver peroxisomes and degrades oxidized proteins. Cell Struct Funct 25: 309-315 (2000).
52. Edland SD. Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease. J Mol Neurosci 23: 213-217 (2004).
53. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162: 313-319 (2003).
54. Hung MC, Hayase K, Yoshida R, Sato M, Imaizumi K. Cerebral protein kinase C and its mRNA level in apolipoprotein E-deficient mice. Life Sci 69: 1419-1427 (2001). (Pubitemid 32758709)
55. Brune S, Kolsch H, Ptok U, Majores M, Schulz A, Schlosser R, et al. Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease. J Neural Transm 110: 1041-1050 (2003).
56. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW and Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264: 850-852 (1994). (Pubitemid 24193454)
57. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294: 1354-1357 (2001).
58. Rodriguez JA, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte M, et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167: 953-960 (2004).
59. Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, et al. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging 24: 637-643 (2003).
60. Karten B, Vance DE, Campenot RB and Vance JE. Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann-Pick C1-deficient neurons. J Neurochem 83: 1154-1163 (2002). (Pubitemid 35407407)